'Developing and delivering mRNA lipid nanoparticle therapeutics’ - BioTechniques Interview with Örn

May 27, 2025

“The mRNA-LNP approach is perfect because it creates the gene editing system in a transient way, in the right cells and the right spots in the genome – like fixing a typo in a large computer program.”

— Örn on the future of mRNA-based LNP therapies

Recorded at ELRIG Research & Innovation 2025, this interview from the BioTechniques International Journal of Life Sciences features Örn from Axelyf discussing how mRNA lipid nanoparticle (LNP) technology is enabling the delivery of complex therapeutics like antibodies. These nanoparticles offer a versatile platform for delivering mRNA to specific tissues, with ongoing research focused on improving stability, reducing inflammation, and expanding tissue targeting. Their potential to enable safe, transient gene editing marks a major advance in precision medicine, and Axelyf is well positioned to pioneer this technology. Learn more about LNPs and their future impact — click here to view the full article.